Interaxon Raises $9.5M in Series C Funding

interaxon

Interaxon, a Toronto, Canada-based consumer neurotechnology company behind Muse, a brain-sensing headband that helps users refocus during the day and recover overnight, raised $9.5M in Series C funding.

The round was led by BDC Capital, Alabaster, Export Development Canada, Phyto Partners, Iter Investments, Intretech, and The Clavis Foundation.

The company intends to use the funds to enrich its brain health platform through launching an integrated wellness membership model and further research and validation of an industry-first feature tracking longitudinal changes in the brain. Interaxon will also expand its offerings for third-party developers, researchers, clinicians and other strategic partnerships and invest in key strategic partnerships including SDK and research partnerships opportunities that leverage their world leading EEG technology platform in the development of data-driven studies and systems that will support the advancement of neuroscience, neurotechnology and brain health at large.

Led by Ariel Garten, Interaxon is a company working in the neurotechnology space, with a brain and biosensor platform of hardware and software products, a data-cloud infrastructure, consumer and licensable B2B products, a large database of brain data in the world, and an IP fortress with several fundamental granted brain, biosignal, VR and AR patents with early priority dates.

Expanding their brain health platform offerings, the company’s brain performance measurement will allow users to compare themselves to various groups across the broader population, and against their own historical values over time. A recent discovery from its R&D team has showcased new patterns in their extensive EEG database with strong indications of brain health. Interaxon aims to leverage these patterns through the development of metrics that will provide users meaningful insights into brain health and lifestyle factors (i.e. meditation, sleep, alcohol, stress, exercise, diet, etc.) that affect it. These personalized insights along with other new biosensor trend reports will roll out later this year, and will be included in the new membership program.

Interaxon is headquartered in Toronto, Canada, and has subsidiaries in the U.S. and Ireland.

FinSMEs

11/08/2022